

## CME INFORMATION

### **Evolution in Massive and Sub-Massive Pulmonary Embolism Treatment Part 2** **April 1, 2021 - April 1, 2022**

#### **Target Audience**

The webinar is designed to meet the needs of cardiologists, surgeons, internists, residents, fellows in training, nurses, nurse practitioners, physician assistants, pharmacists, health care technicians, and other health care providers and investigators who participate in the management of patients with coronary, peripheral, structural, and arrhythmic cardiovascular diseases.

#### **Educational Goal**

The purpose of this educational activity is to provide participants with knowledge of acute pulmonary embolism treatment.

#### **Learning Objectives**

- Explain the importance of PERT program and its importance on clinical outcomes
- Discuss the components of a system wide PERT program and how it can be functional
- Identify best patients for anticoagulation alone, lysis, endovascular embolectomy, or systemic lysis
- List steps for catheter directed pharmaco-mechanical lysis, including facilitated lysis
- List steps for endovascular thrombectomy

#### **Accreditation**

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of *CMEsolutions* and Cardiovascular Innovations Foundation. The *CMEsolutions* is accredited by the ACCME to provide continuing medical education for physicians.

The *CMEsolutions* designates this enduring activity for a maximum of 1 *AMA PRA Category 1 Credits*.™ Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Start Date:** April 1, 2021

**End Date:** April 1, 2022

#### **PARTICIPATION REQUIREMENTS**

1. Read CME Information
2. Participate in virtual presentations
3. Logon to the following URL: <https://online-med-edu.com/cvievolution/412021>
4. Complete evaluation, credit request form, and download or print credit statement

## **FACULTY AND DISCLOSURES**

*CMEsolutions* requires everyone in a position to control the content of this activity to disclose any relevant financial conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by *CMEsolutions* for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. *CMEsolutions* has mitigated all conflicts of interest prior to this educational activity.

### ***Subhash Banerjee, MD***

Chief of Cardiology, VA North Texas Health Care System  
Dallas, TX

Disclosed the following relevant financial relationships: AstraZeneca-Speaker's Bureau; Boston Scientific- Institutional Research Grant; Livmore Inc.-Consultant

### ***Christopher Morris Huff, MD***

Interventional Cardiologist, Riverside Methodist Hospital  
Columbus, OH

Disclosed the following relevant financial relationships: Inari Medical-Speaking, Teaching, Consulting; Surmodics-Consulting; Boston Scientific-Speaking, Teaching

### ***Jay Giri, MD***

Cardiologist, Penn Medicine  
Philadelphia, PA

Disclosed the following relevant financial relationships: Inari, Boston Scientific-Advisory Board

### ***Jun Li, MD***

Interventional Cardiology, University Hospitals  
Parma, OH

Disclosed the following relevant financial relationships: Medtronic, Inari Medical-Advisory Board; Abbott Vascular, Philips-Consultant

### ***Mehdi Shishehbor, DO, MPH, PhD***

Director, Cardiovascular Interventional Center, University Hospitals Cleveland Medical Center  
Cleveland, OH

Mehdi Shishehbor has disclosed the following relevant financial relationships: Abbott Vascular, Boston Scientific Corporation, Medtronic, Philips, and Terumo- Advisory Board

## **Planner Disclosures**

No member of *CMEsolutions* or Cardiovascular Innovations Foundation has any relevant financial relationships to disclose.

## **Off-label Use**

This activity may contain discussion of unlabeled and/or investigational uses of agents not approved by the FDA. Please consult the prescribing information for each product.

## **Commercial Support**

Boston Scientific  
Inari Medical

## **Privacy Policy**

*CMEsolutions* Privacy and Confidentiality Policy: [www.online-med-edu.com/privacypolicy.pdf](http://www.online-med-edu.com/privacypolicy.pdf)  
*CMEsolutions* can be contacted at [info@cmesolutions.org](mailto:info@cmesolutions.org).

**Software Requirements**

**PC**

Windows 2000 or higher

Internet Explorer 5.5 or Firefox

Adobe Acrobat Reader

**MAC**

Mac OS 10.2.8

Safari

Adobe Acrobat Reader